Microgentas focuses on integrated exosome isolation and miRNA extraction. The company provides solutions to sample preparation challenges with its core technologies, offering faster, cost-effective, scalable, user-friendly exosome isolation kits: ExoCAS™, ExoPAS™, ExoFilter™, ExoTFF™ and exosomal microRNA extraction kits, miRQuick™. Microgentas is also developing EV research related to exosome-based biomarkers for diagnosing and monitoring breast cancer, collaborating with Korea University Anam Hospital. Also collaborating with cosmetic companies who is willing to use exosome as their ingredients.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 안암로 145, 성북구, 서울시,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://microgentas.com/en
- Keywords
- liquid biopsy, exosome isolation, extracellular vesicles, cancer research, breast cancer, EVs.
- HQ
- 서울시
Microgentas Questions
Microgentas's website is https://microgentas.com/en
Microgentas's LinkedIn profile is https://kr.linkedin.com/company/microgentas
Microgentas has
6 employees.
View email and phone details for 6
employees at Microgentas.
Microgentas's industry is
Biotechnology Research
Microgentas's top competitors are
Cellin Technologies,
Medirama Inc.,
Hansabiomed Life Sciences Ltd,
Exosomics Spa,
Gearbox Biosciences,
Ascentia,
Exosome Diagnostics, A Bio-Techne Brand,
Exosome Sciences Inc,
Exodus Bio,
Conveyxo.
Microgentas's categories are Biotechnology Research
Microgentas's founding year is 2021
